| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 355 | 2019 |
| Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism R Lecumberri, A Alfonso, D Jiménez, CF Capitán, P Prandoni, PS Wells, ... Thrombosis and haemostasis 110 (10), 834-843, 2013 | 133 | 2013 |
| Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Leukemia 35 (12), 3542-3550, 2021 | 110 | 2021 |
| Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative … G Montalban-Bravo, K Takahashi, K Patel, F Wang, S Xingzhi, ... Oncotarget 9 (11), 9714, 2018 | 71 | 2018 |
| A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer A Abdulla, WM Davis, N Ratnaweera, E Szefer, BB Scott, AYY Lee Thrombosis and haemostasis 120 (04), 702-713, 2020 | 55 | 2020 |
| Inusual arribazón de Sargassum fluitans (Børgesen) Børgesen en la costa centro-sur de Cuba A Moreira, A Alfonso | 54 | 2013 |
| Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies YM Abaza, TM Kadia, EJ Jabbour, MY Konopleva, G Borthakur, ... Cancer 123 (24), 4851-4859, 2017 | 51 | 2017 |
| Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents A Alfonso, G Montalban‐Bravo, K Takahashi, EJ Jabbour, T Kadia, ... American journal of hematology 92 (7), 599-606, 2017 | 47 | 2017 |
| Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design A Aguilera-Diaz, I Vazquez, B Ariceta, A Mañú, Z Blasco-Iturri, ... PloS one 15 (1), e0227986, 2020 | 44 | 2020 |
| A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials G Montalban-Bravo, X Huang, E Jabbour, G Borthakur, CD DiNardo, ... Leukemia 31 (2), 318-324, 2017 | 44 | 2017 |
| RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated intravenous (IV) and … C Carlo-Stella, R Mazza, S Manier, T Facon, SS Yoon, Y Koh, SJ Harrison, ... Blood 140 (Supplement 1), 397-399, 2022 | 39 | 2022 |
| High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients R Lecumberri, M Marqués, E Panizo, A Alfonso, A García-Mouriz, ... Thrombosis and haemostasis 110 (07), 184-190, 2013 | 38 | 2013 |
| Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy I Ganan-Gomez, H Yang, F Ma, G Montalban-Bravo, N Thongon, ... Nature medicine 28 (3), 557-567, 2022 | 35 | 2022 |
| Screening for occult malignancy with FDG‐PET/CT in patients with unprovoked venous thromboembolism A Alfonso, M Redondo, T Rubio, B Del Olmo, P Rodríguez‐Wilhelmi, ... International journal of cancer 133 (9), 2157-2164, 2013 | 35 | 2013 |
| CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome P Rodriguez-Marquez, ME Calleja-Cervantes, G Serrano, A Oliver-Caldes, ... Science Advances 8 (39), eabo0514, 2022 | 32 | 2022 |
| Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases MM Patnaik, AA Pierola, R Vallapureddy, FF Yalniz, TM Kadia, ... Leukemia 32 (11), 2512-2518, 2018 | 26 | 2018 |
| CAR T-cells in multiple myeloma are ready for prime time P Rodríguez-Otero, F Prósper, A Alfonso, B Paiva, JFS Miguel Journal of Clinical Medicine 9 (11), 3577, 2020 | 24 | 2020 |
| Clonal hematopoiesis of indeterminate potential–associated mutations and risk of comorbidities in patients with myelodysplastic syndrome K Naqvi, K Sasaki, G Montalban‐Bravo, A Alfonso Pierola, M Yilmaz, ... Cancer 125 (13), 2233-2241, 2019 | 20 | 2019 |
| Current therapy of the patients with MDS: walking towards personalized therapy ML Palacios-Berraquero, A Alfonso-Piérola Journal of clinical medicine 10 (10), 2107, 2021 | 18 | 2021 |
| Predictors for residual pulmonary vascular obstruction after unprovoked pulmonary embolism: implications for clinical practice—the PADIS-PE trial L Raj, P Robin, R Le Mao, E Presles, C Tromeur, O Sanchez, G Pernod, ... Thrombosis and haemostasis 119 (09), 1489-1497, 2019 | 18 | 2019 |
